Tumor vascular infarction: prospects and challenges
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Induction of thrombosis in tumor vasculature represents an appealing strategy for combating cancer. Formation of fibrin clots may be sufficient to occlude the blood vessels that feed tumor cells, contributing to massive ischemia, vascular infarction, and the subsequent necrosis and apoptosis of neoplastic cells. This approach called as tumor vascular infarction was pioneered by Huang et al. (Science 275:547-550, 1997). Since then, different vascular targeting moieties were linked to a truncated form of human tissue factor (tTF), to generate coaguligands with selective thrombotic activities on tumor neovasculature. In contrast to the wide clinical application of angiogenesis inhibitors and tumor vascular disrupting agents, tTF-NGR is the only example of clinically tested coaguligands. Notably, among these three tumor vascular targeting approaches, tumor vascular infarction is the only modality manifesting long-term curative potential in mice. Translation of this worthy approach has been limited, as induction of thrombosis by TF fusion proteins is leaky. In this review, we describe the clinical significance of tumor vascular infarction, highlight its advantages and disadvantages, and propose a novel strategy for expediting its translation to clinical settings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Tumor hypoxia induces angiogenesis by activating the expression of vascular endothelial growth factor (VEGF) [3].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [3]
In the citing paper
“To this end, most primary strategies are directed at inhibiting tumor angiogenesis by blocking either growth factors or factors involved in endothelial cell migration, survival, and proliferation (Fig. 2a) [50] (see for review [3, 51]).”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [3]
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Disrupting tumour blood vessels
Tozer, G. M., Kanthou, C., & Baguley, B. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1628 · Cited by 930
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691
Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
Camerer, E., Huang, W., & Coughlin, S. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5255 · Cited by 675
Vascular Targeting Agents as Cancer Therapeutics
Thorpe, P. E. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0642-03 · Cited by 577
Combination bacteriolytic therapy for the treatment of experimental tumors
Dang, L. H., Bettegowda, C., Huso, D. L., Kinzler, K. W., & Vogelstein, B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251543698 · Cited by 563
MazF Cleaves Cellular mRNAs Specifically at ACA to Block Protein Synthesis in Escherichia coli
Zhang, Y., Zhang, J., Hoeflich, K. P., Ikura, M., Qing, G., & Inouye, M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00402-7 · Cited by 562
de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70509-0 · Cited by 529
Zhao, M., Yang, M., Li, X.-M., Jiang, P., Baranov, E., Li, S., Xu, M., Penman, S., & Hoffman, R. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408422102 · Cited by 484
Zwicker, J. I., Liebman, H. A., Neuberg, D., Lacroix, R., Bauer, K. A., Furie, B. C., & Furie, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0371 · Cited by 479
Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature
Huang, X., Molema, G., King, S., Watkins, L., Edgington, T. S., & Thorpe, P. E. (1997) · Science · doi:10.1126/science.275.5299.547 · Cited by 477
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
Bacteria in cancer therapy: a novel experimental strategy
Patyar, S., Joshi, R., Byrav, D. P., Prakash, A., Medhi, B., & Das, B. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-21 · Cited by 340
Tumor-derived tissue factor–positive microparticles and venous thrombosis in cancer patients
Geddings, J. E., & Mackman, N. (2013) · Blood · doi:10.1182/blood-2013-04-460139 · Cited by 336
He, S., Liu, Z., Oh, D.-Y., & Thiele, C. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00001 · Cited by 325
Angiogenesis inhibition: A review
Auerbach, W., & Auerbach, R. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90027-2 · Cited by 321
Vascular attack as a therapeutic strategy for cancer
Denekamp, J. (1990) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046365 · Cited by 264
El‐Kenawi, A. E., & El‐Remessy, A. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12344 · Cited by 253
Insights into the mRNA Cleavage Mechanism by MazF, an mRNA Interferase
Zhang, Y., Zhang, J., Hara, H., Kato, I., & Inouye, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411811200 · Cited by 236
Nilsson, F., Kosmehl, H., Zardi, L., & Neri, D. (2001) · PubMed · Cited by 235
The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy
van Beijnum, J. R., Nowak-Sliwinska, P., Huijbers, E. J. M., Thijssen, V. L., & Griffioen, A. W. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010215 · Cited by 211
Kim, S. H., Castro, F., Paterson, Y., & Gravekamp, C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4855 · Cited by 210
mazEF: a chromosomal toxin-antitoxin module that triggers programmed cell death in bacteria
Engelberg-Kulka, H., Hazan, R., & Amitai, S. (2005) · Journal of Cell Science · doi:10.1242/jcs.02619 · Cited by 165
Mechanisms of resistance to anti-angiogenesis therapies
Giuliano, S., & Pagès, G. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.002 · Cited by 158
Disrupting established tumor blood vessels: An emerging therapeutic strategy for cancer
McKeage, M. J., & Baguley, B. C. (2010) · Cancer · doi:10.1002/cncr.24975 · Cited by 148
Patterson, D. M., & Rustin, G. J. S. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.03.014 · Cited by 146
Vascular disrupting agents: a new class of drug in cancer therapy
Gaya, A. M., & Rustin, G. J. S. (2005) · Clinical Oncology · doi:10.1016/j.clon.2004.11.011 · Cited by 145
Bieker, R., Kessler, T., Schwöppe, C., Padró, T., Persigehl, T., Bremer, C., Dreischalück, J., Kolkmeyer, A., Heindel, W., Mesters, R. M., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150318 · Cited by 139
Antiangiogenic tumour therapy: will it work?
Augustin, H. G. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01211-5 · Cited by 138
Ran, S., Gao, B., Duffy, S. L., Watkins, L. R., Rote, N., & Thorpe, P. E. (1998) · PubMed · Cited by 128
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF
Guba, M., Yezhelyev, M., Eichhorn, M. E., Schmid, G., Ischenko, I., Papyan, A., Graeb, C., Seeliger, H., Geissler, E. K., Jauch, K.-W., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3540 · Cited by 127
Tissue Factor – A Receptor Involved in the Control of Cellular Properties, Including Angiogenesis
Chen, J., Bierhaus, A., Schiekofer, S., Andrassy, M., Chen, B., Stern, D. M., & Nawroth, P. P. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1616231 · Cited by 113
Jiang, X., Bailly, M. A., Panetti, T. S., Cappello, M., Konigsberg, W. H., & Bromberg, M. E. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00545.x · Cited by 106
Friedlos, F., Lehouritis, P., Ogilvie, L., Hedley, D., Davies, L., Bermudes, D., King, I., Martin, J., Marais, R., & Springer, C. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4800 · Cited by 91
Tumor-targeting prodrug-activating bacteria for cancer therapy
Cheng, C.-M., Lu, Y.-L., Chuang, K.-H., Hung, W., Shiea, J., Su, Y.-C., Kao, C.-H., Chen, B.-M., Roffler, S. R., & Cheng, T.-L. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.10 · Cited by 88
Insights into the specificity of RNA cleavage by the Escherichia coli MazF toxin
Muñoz‐Gómez, A. J., Santos‐Sierra, S., Berzal‐Herranz, A., Lemonnier, M., & Díaz‐Orejas, R. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.05.005 · Cited by 88
Prostate-specific membrane antigen directed selective thrombotic infarction of tumors.
Liu, C., Huang, H., Doñate, F., Dickinson, C. D., Santucci, R. A., El-Sheikh, A., Vessella, R., & Edgington, T. S. (2002) · PubMed · Cited by 79
Cesca, M., Bizzaro, F., Zucchetti, M., & Giavazzi, R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00259 · Cited by 75
Keßler, T., Bieker, R., Padró, T., Schwöppe, C., ten Persigehl, T., Bremer, C., Kreuter, M., Berdel, W. E., & Mesters, R. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0389 · Cited by 74
Tumor Vasculature Targeting Through NGR Peptide-Based Drug Delivery Systems
Corti, A., & Curnis, F. (2011) · Current Pharmaceutical Biotechnology · doi:10.2174/138920111796117373 · Cited by 70
Single protein production (SPP) system in Escherichia coli
Suzuki, M., Mao, L., & Inouye, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.252 · Cited by 69
Fabbrini, M., Trachsel, E., Soldani, P., Bindi, S., Alessi, P., Bracci, L., Kosmehl, H., Zardi, L., Neri, D., & Neri, P. (2005) · International Journal of Cancer · doi:10.1002/ijc.21412 · Cited by 67
Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Wahl, O., Oswald, M., Tretzel, L., Herres, E., Arend, J., & Efferth, T. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796391570 · Cited by 65
Live bacteria as anticancer agents and tumor-selective protein delivery vectors.
Bermudes, D. G., Zheng, L.-M., & King, I. (2002) · PubMed · Cited by 63
Hu, P., Yan, J., Sharifi, J., Bai, T., Khawli, L. A., & Epstein, A. L. (2003) · PubMed · Cited by 62
Fujita, K., Sano, D., Kimura, M., Yamashita, Y., Kawakami, M., Ishiguro, Y., Nishimura, G., Matsuda, H., & Tsukuda, M. (2007) · Oncology Reports · doi:10.3892/or.18.1.47 · Cited by 61
Inouye, M. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20801 · Cited by 57
Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions
Liang, W., Ni, Y., & Chen, F. (2016) · Oncotarget · doi:10.18632/oncotarget.6999 · Cited by 57
Perspectives in vector development for systemic cancer gene therapy.
Hatefi, A., & Canine, B. (2009) · PubMed · Cited by 40
Wu, X., Ma, W., Gurung, K., & Guo, C.-H. (2012) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.09.017 · Cited by 39
Contributions of thrombin targets to tissue factor‐dependent metastasis in hyperthrombotic mice
Yokota, N., Zarpellon, A., Chakrabarty, S., Bogdanov, V. Y., Gruber, A., Castellino, F., Mackman, N., Ellies, L. G., Weiler-Guettler, H., Ruggeri, Z. M., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12442 · Cited by 36
Bhavsar, T. M., Patel, S. N., & Lau‐Cam, C. A. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-s1-s19 · Cited by 34
Brand, C., Schliemann, C., Ring, J., Keßler, T., Bäumer, S., Angenendt, L., Mantke, V., Ross, R., Hintelmann, H., Spieker, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6725 · Cited by 21
Su, M., Samoszuk, M. K., Wang, J., & Nalcioğlu, O. (2002) · NMR in Biomedicine · doi:10.1002/nbm.730 · Cited by 16
Regression of Solid Tumors by Induction of MazF, a Bacterial mRNA Endoribonuclease
Shimazu, T., Mirochnitchenko, O., Phadtare, S., & Inouye, M. (2014) · Microbial Physiology · doi:10.1159/000365509 · Cited by 15
Okamoto, M., Chono, H., Kawano, Y., Saito, N., Tsuda, H., Inoue, K., Kato, I., Mineno, J., & Baba, M. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.131 · Cited by 15
Berdel (2010) · International Journal of Oncology · doi:10.3892/ijo_00000790 · Cited by 15
Targeting the Vasculature of Colorectal Carcinoma with a Fused Protein of (RGD) 3‐tTF
Huang, Z., Zhao, Y., Luo, W., You, J., Li, S.-W., Yi, W.-C., Wang, S., Yan, J., & Luo, Q. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/637086 · Cited by 12
Saito, N., Chono, H., Shibata, H., Ageyama, N., Yasutomi, Y., & Mineno, J. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.20 · Cited by 12
Huang, F., Li, Y., Wang, H., Huang, Y., Lin, Y., & Tan, G. (2008) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b0820120 · Cited by 7
Flipping the wound that doesn't heal: the upside of coagulation in cancer
Teicher, B. A. (2009) · Blood · doi:10.1182/blood-2009-03-207316 · Cited by 5
Djeha, H., Shah, K., McGeever, G., Dobinson, D., & Green, C. (2007) · Cancer Research · Cited by 5
A new role for Pk: finding the 1 in a million
Hillyer, C. D. (2009) · Blood · doi:10.1182/blood-2009-02-203299 · Cited by 2
Cited by
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“2a ) [50] (see for review [3, 51] ).”
BackgroundInfluentialSelf-citationAdvances in nanomaterial-based targeted drug delivery systems
Cheng, X., Xie, Q., & Sun, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1177151 · Cited by 395
“Usually, tumor infarction can be acutely induced, and its effects can occur within a few hours (Jahanban-Esfahlan et al., 2017).”
BackgroundAdvances of medical nanorobots for future cancer treatments
Kong, X., Gao, P., Wang, J., Fang, Y., & Hwang, K. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01463-z · Cited by 238
“They have demonstrated promising therapeutic effects in animal models [353].”
BackgroundModulating tumor hypoxia by nanomedicine for effective cancer therapy
Jahanban‐Esfahlan, R., de la Guardia, M., Ahmadi, D., & Yousefi, B. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25859 · Cited by 201
Self-citationSmart Nanotherapeutic Targeting of Tumor Vasculature
Li, Z., Di, C., Li, S., Yang, X., & Nie, G. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00283 · Cited by 196
Metadata
- Authors
- Jahanban-Esfahlan, R., Seidi, K., & Zarghami, N.
- Affiliations
- Tabriz University of Medical Sciences (IR)
- Corresponding author
- Zarghami, Nosratollah
- Venue
- International Journal of Hematology
- Published
- 2017-01-02
- Volume
- 105
- Issue
- 3
- Pages
- 244-256
- ISSN
- 0925-5710 (ISSN-L)
- 1865-3774
- OpenAlex
- W2567676221
- Cited by
- 88
- References
- 64
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 10 · 2023: 15 · 2022: 16 · 2021: 15 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 5
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Hematology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Iran National Science Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- tumor neovasculature, tissue factor, thrombosis, fibrin clot, tumor ischemia, tumor necrosis, vascular targeting, angiogenesis inhibitors, clinical translation
- MeSH terms
- Animals, Humans, Neoplasms, Neovascularization, Pathologic, Thromboplastin, Thrombosis, Angiogenesis Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.